– DENMARK, Ballerup – LEO Pharma today announced the appointment of Paul Navarre to its Board of Directors.
“With his impressive career, Paul brings extensive strategic and commercial experience from the global biotech and dermatology market, that will be of great value to LEO Pharma in its ambitions to create future growth and become a top five company within medical dermatology. I am excited to be working together with Paul going forward”, said Board Chairman, Jesper Brandgaard.
About Paul Navarre
Paul Navarre currently serves as chairman of the Board of Directors at HTL and Arkopharma, as Vice-Chairman of Hallura, and as Strategic Advisor to other companies. From 2017-2020 he held the position as CEO of Ferring US Holafternt to ten years at Allergan, others as President of International Operations (except the US) and President of EMEA. Before that, he spent 15 years at Procter & Gamble managing multiple countries and global pharmaceuticals and Health and beauty care brands.
Paul Navarre has a solid track record of delivering sustained top-line line growth and building high-performance organizations in the specialty pharmaceutical business through scientific innovation and customer-centricntric approaches.
“It’s a privilege to join the Board of Directors at LEO Pharma at this time in the company’s history. With its ongoing transformation, many steps have already been taken to position the company for future growth and I look much forward to being part of continuing this development”, said Paul Navarre.
Paul Navarre was elected one of the Top 100 Most Inspiring People by PharmaVoice in 2019. In 2021 he completed the INSEAD Corporate Governance Course.
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology. Today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients worldwide. In 2021, the company generated net sales of DKK 9,957 million.
For more information: https://www.leo-pharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.